0I3I Stock Chart & Stats
$69.68
$1.11(1.57%)
At close: 4:00 PM EDT
$69.68
$1.11(1.57%)
Day’s Range― - ―
52-Week Range$57.64 - $89.11
Previous CloseN/A
Volume88.00
Average Volume (3M)295.00
Market Cap
$13.57B
Enterprise Value$14.59K
Total Cash (Recent Filing)$138.80M
Total Debt (Recent Filing)$2.46B
Price to Earnings (P/E)59.0
Beta1.02
Next Earnings
Sep 09, 2026EPS Estimate
1.12Next Dividend Ex-DateN/A
Dividend Yield0.02%
Share Statistics
EPS (TTM)1.18
Shares Outstanding195,030,620
10 Day Avg. Volume288
30 Day Avg. Volume295
Financial Highlights & Ratios
PEG Ratio-8.14
Price to Book (P/B)1.70
Price to Sales (P/S)3.42
P/FCF Ratio32.24
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$80.00Price Target Upside14.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)4.63
Revenue Forecast (FY)$4.31B
Bulls Say, Bears Say
Bulls Say
Global Contact-lens Leadership And Product MomentumLeadership in global contact lenses, combined with growth in daily silicone hydrogel and Biofinity products, supports durable customer reach and category relevance. This scale can reinforce innovation, distribution strength, and recurring demand across the core vision-care franchise.
Steady Revenue Growth With Maintained FY2026 GuidanceMaintained revenue guidance indicates management still expects the business to expand despite regional and margin headwinds. A combination of reported and organic growth provides a credible base for continued investment, operating scale, and earnings development over the next several quarters.
Moderate Leverage And Improving Balance-sheet PositionModerate leverage and a substantial equity base provide financial flexibility for investment, strategic initiatives, and working-capital needs. The improvement in debt-to-equity reduces balance-sheet pressure and gives Cooper capacity to navigate volatility while pursuing its longer-term growth priorities.
Bears Say
Recent Profitability DeteriorationThe recent decline in net, EBIT, and EBITDA margins shows that top-line growth is not currently translating into equivalent earnings power. If this pressure persists, it could limit reinvestment capacity, reduce operating leverage, and make future profit growth more dependent on execution improvements.
Weaker Free-cash-flow ConversionLower free cash flow and weaker conversion from earnings indicate reduced cash-generation quality in the latest period. Persistent deterioration could constrain capital allocation, increase reliance on balance-sheet resources, and make the reaffirmed multi-year cash-flow targets harder to achieve.
Litigation Settlement Creates Substantial Cash And Earnings BurdenThe sizeable fertility-business settlement creates a meaningful near-term cash outflow and reduces reported earnings, even though it is excluded from non-GAAP results. Concentrated payouts can restrict financial flexibility and distract management while the business continues operational and strategic initiatives.
Cooper Co News
0I3I FAQ
What was Cooper Co’s price range in the past 12 months?
Cooper Co lowest share price was $57.64 and its highest was $89.11 in the past 12 months.
What is Cooper Co’s market cap?
Cooper Co’s market cap is $13.57B.
When is Cooper Co’s upcoming earnings report date?
Cooper Co’s upcoming earnings report date is Sep 09, 2026 which is tomorrow.
How were Cooper Co’s earnings last quarter?
Cooper Co released its earnings results on Jun 04, 2026. The company reported $1.21 earnings per share for the quarter, beating the consensus estimate of $1.104 by $0.106.
Is Cooper Co overvalued?
According to Wall Street analysts Cooper Co’s price is currently Undervalued.
Does Cooper Co pay dividends?
Cooper Co pays a Semiannually dividend of $0.009 which represents an annual dividend yield of 0.02%. See more information on Cooper Co dividends here
What is Cooper Co’s EPS estimate?
Cooper Co’s EPS estimate is 1.12.
How many shares outstanding does Cooper Co have?
Cooper Co has 195,030,620 shares outstanding.
What happened to Cooper Co’s price movement after its last earnings report?
Cooper Co reported an EPS of $1.21 in its last earnings report, beating expectations of $1.104. Following the earnings report the stock price went up 7.633%.
Which hedge fund is a major shareholder of Cooper Co?
Currently, no hedge funds are holding shares in GB:0I3I
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cooper Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$80.00 (14.81% Upside)
$80.00 (14.81% Upside)
Blogger Sentiment
Bullish
GB:0I3I Sentiment 66%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.55%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cooper Co
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
0I3I Company Deck
0I3I Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally positive operational and financial picture: record quarterly revenue and strong non-GAAP EPS, meaningful margin expansion, robust product-level growth (notably MiSight and CooperSurgical fertility), improved free cash flow and active strategic initiatives. However, material near-term headwinds create caution — a significant litigation settlement affecting GAAP results and concentrated cash outflows, Asia Pacific market softness tied to legacy product rationalization and consumer weakness (especially Japan/China), and expected short-term gross margin pressure from FX, tariffs and inventory optimization. Management balanced conservative guidance with a clear plan for capital allocation and strategic review progress, leaving the near-term outlook mixed but supported by strong execution and long-term cash-generation targets.View all GB:0I3I earnings summaries0I3I Net sales Breakdown
67.05% CooperVision
32.95% CooperSurgical
0I3I Stock 12 Month Forecast
Average Price Target
$80.00
▲(14.81% Upside)
Technical Analysis
Baxter International
―
Merit Medical Systems
―
Staar Surgical
―
Teleflex
―
Bausch + Lomb Corporation
―